System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Philippe Gabriel Steg, MD is an expert in Cardiology at Hôpital Bichat-Claude-Bernard (France). As of October 2026, ScienceLeadR ranks Philippe Gabriel Steg in the top 1% of experts worldwide for Myocardial Ischemia, Coronary Disease and Arterial Occlusive Diseases. Philippe Gabriel Steg has authored 1,942 publications, the most recent in 2026, and is an investigator in 116 clinical trials, 8 of them ongoing. SLR score: 7,565 (community average: 125). How the SLR is computed.

LeadR Profile

Philippe Gabriel Steg, MD Hôpital Bichat-Claude-Bernard France
7 565 ScienceLeadR Reputation 7565

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Hôpital Bichat-Claude-Bernard

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1942

Citations

Citations: 230 848 1st author: 117 Last author: 266 Unique author: 17

Main journals

J Am Coll Cardiol 263
Eur Heart J 236
Circulation 210
Am Heart J 101
N Engl J Med 71

Best Journals

N Engl J Med 71
Circulation 62
Eur Heart J 55

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial.
PMID 42772753 — air pollution, aspirin, air, environmental pollution, random allocation		Eur Heart J Cardiovasc Pharmacother20260
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PMID 42669300 — myocardial infarction, heart failure, heart, therapeutics		Lancet Top journal20262
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide		JAMA Cardiol20260
Impact of the new 2024 ESC blood pressure classification in a low-risk cohort: the 70 mmhg diastolic threshold may reduce risk discrimination in primary prevention.
PMID 42695468 — hypertension, life style, body mass index, blood, cardiovascular diseases, blood pressure, classification, primary prevention		J Hypertens20260
Benefit of Sotagliflozin Across the Full Range of Baseline Blood Pressure in the SOLOIST-WHF Trial.
PMID 42670741 — blood, heart failure, blood pressure		JACC Heart Fail20260

Clinical Studies 116

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Director: 1

By phase:

Phase 3 65
N/A 29
Phase 4 10
Phase 2 9
Phase 2/Phase 3 3

By status:

Completed 86
Terminated 10
Active not recruiting 7
Unknown 7
Recruiting 5
Not yet recruiting 1

By type:

Interventional 104
Observational 12

By Monocentric/Multicentric:

monocentric 40
multicentric2to4 4
multicentric5to9 3
multicentricup10 69

Main Topics

Cohort/Consortium Investigators 11

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230)
2024-519870-38-00 — safety, cardiovascular diseases		Phase 3Not yet recruiting2026
Rituximab in patients with ST elevation myocardial infarction A phase 2 placebo controlled randomized clinical trial
2022-501893-21-00 — myocardial infarction, st elevation myocardial infarction, rituximab		Phase 2Recruiting2022
A randomized double blind placebo controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high risk primary prevention patients (VICTORION 1 PREVENT)
2022-502779-40-00 — cardiovascular diseases, primary prevention		Phase 3Active not recruiting2023
A Trial to Test How AZD0780 Affects Serious Heart Stroke or Vascular Problems in Patients with Heart Stroke or Vascular Disease or at High Risk for Such Issues
2025-520519-14-00 — stroke, heart, cardiovascular diseases, vascular diseases		Phase 3Recruiting2025
A Phase 3 Randomized Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of MK 0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
2022-502781-24-01 — heart diseases, safety, heart, cardiovascular diseases, coronary disease		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS